This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leeming, D. J. Articles by Byrjalsen, I. Search for Related Content PubMed PubMed Citation Articles by Leeming, D. J. Articles by Byrjalsen, I. Related Collections Oncogenesis Oncogenesis: Biomarkers

Alpha CTX as a Biomarker of Skeletal Invasion of Breast Cancer: Immunolocalization and the Load Dependency of Urinary Excretion

¹ Nordic Bioscience Diagnostics A/S, Herlev, Denmark; ² Institute of Bone Pathology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; ³ Cancer Institute Hospital, Tokyo, Japan; and ⁴ Center for Clinical and Basic Research, Ballerup, Denmark

Requests for reprints: Diana J. Leeming, Nordic Bioscience A/S, Herlev Hovedgade 207, DK-2730 Herlev, Denmark. Phone: 45-4452-5216; Fax: 45-4454-8888. E-mail: djl{at}nordicbioscience.com

We recently showed that increased urinary excretion of the cross-linked, nonisomerized form of the C-telopeptide of collagen type I (CTX) could be a sensitive indicator of the presence of bone metastases in breast cancer patients. The present study was sought to investigate (a) the localization of CTX epitopes in the proximity of a bone metastasis and (b) the relationship between number of metastases and the urinary excretion of CTX. Adjacent bone sections from breast cancer patients were stained for the presence of tumor cells (anti-cytokeratin antibody), osteoclasts (TRAcP activity), and CTX (anti-CTX antibody). The association between the extent of metastatic bone disease and urinary excretion of CTX measured with ELISA was assessed in 90 breast cancer patients (45 with bone metastasis and 45 without bone metastasis). Immunohistochemistry revealed accumulation of TRAcP-positive osteoclasts and intense staining for CTX epitopes in the proximity of cytokeratin-positive bone metastasis. Areas of CTX staining showed unstructured bone tissue under polarized light. In addition, there was a significant linear association between the number of bone metastases and the urinary levels of CTX in breast cancer patients with metastatic bone disease, independent of age and body mass index (r = 0.56, P < 0.001). The estimated relative increases in CTX associated with the presence of one, two, or three metastases are 38%, 57%, and 81%, respectively. Taken into account the 17% intraindividual variation of the assay, CTX could be a sensitive biochemical marker for the close monitoring of cancer patients aiming the facilitation of early metastasis detection. (Cancer Epidemiol Biomarkers Prev 2006;15(7):1392–5)

This article has been cited by other articles:

				D. J. Leeming, A. Hegele, I. Byrjalsen, R. Hofmann, P. Qvist, M. A. Karsdal, A. J. Schrader, R. Wagner, and P. Olbert Biochemical Markers for Monitoring Response to Therapy: Evidence for Higher Bone Specificity by a Novel Marker Compared with Routine Markers Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1269 - 1276. [Abstract] [Full Text] [PDF]

				P. Garnero New Biochemical Markers of Bone Turnover IBMS BoneKEy, March 1, 2008; 5(3): 84 - 102. [Abstract] [Full Text] [PDF]